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CYCLOOXYGENASE (COX), existing as the COX-1 and COX-
2  isoforms,  converts  arachidonic  acid  to  prosta-
glandin  H2,  which  is  then  further  metabolized  to
various prostaglandins. Vascular endothelial growth
factor (VEGF) has been shown to play important roles
in  inflammation  and  is  upregulated  by  the  prosta-
glandin E series through COX-2 in several cell types.
Here, we have investigated the effects of VEGF on the
COX  isoform  expressed  in  human  umbilical  vein
endothelial cells (HUVEC). The signalling mechanism
of  the  COX  isoform  expressed  in  endothelial  cells
activated with VEGF will be also investigated using the
tyrosine  kinase  inhibitor,  genistein,  and  protein
kinase C inhibitor, staurosporine. The activity of COX-
2  was  assessed  by  measuring  the  production  of
6-keto-prostaglandin  F1a in  the  presence  of  exoge-
nous  arachidonic  acids  (10 m M,  10 min)  by  enzyme
immunoassay. The expression of COX isoform pro-
tein  was  detected  by  immunoblot  using  specific
antibodies.  Untreated  HUVEC  contained  no  COX-2
protein. In HUVEC treated with VEGF (0.01–50 ng/ml),
COX-2 protein, but not COX-1, and COX activity were
increased in a dose-dependent manner. Interestingly,
the increased COX-2 protein and activity in response
to  VEGF  (10 ng/ml)  was  inhibited  by  the  tyrosine
kinase inhibitor, genistein (0.05–5 mg/ml), but not by
the  protein  kinase  C  inhibitor,  staurosporine
(0.1–10 ng/ml). Thus, the induction of COX-2 by VEGF
in  endothelial  cells  was  mediated  through  protein
tyrosine  kinase,  and  the  uses  of  specific  COX-2
inhibitors  in  these  conditions,  in  which  VEGF  was
involved, might have a role.
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Introduction
Cyclooxygenase (COX) converts arachidonic acid to
prostaglandin H2,1 which is then further metabolized
to various prostaglandins, prostacyclin and thrombox-
ane A2.2 COX exists in at least two isoforms.3 COX-1 is
expressed constitutively in  endothelial cells4 and is
probably  responsible  for  the  production  of  prosta-
glandins  under  physiological  conditions.5 COX-2  is
induced by pro-inflammatory stimuli, including mito-
gens,6 cytokines,7,8 and bacterial lipopolysaccharide,4
in  cells  in  vitro and  in  inflamed  sites  in  vivo.9
However, COX-2 has been shown to be constitutively
expressed in some cell types and tissues such as brain,
spinal  cord,  kidneys,  reproductive  organs,  some
vascular endothelial cell types and species10including
human platelets.11 COX-2 has also been shown to be
upregulated  in  some  conditions  such  as  athero-
sclerosis  and  gastric  ulcer  associated  with  Heli-
cobacter pyroli.12,13These are thought to be physio-
logical  stress  or  pathological  defense  functions  of
COX-2, and raised the hypothesis of whether another
isoform of COX (COX-3) may exist.14
Vascular  endothelial  growth  factor  (VEGF)15 is  a
homodimeric  34–42kDa  heparin-binding  glycopro-
tein with potent angiogenic, mitogenic and vascular
permeability-enhancing  activities  specific  for  endo-
thelial cells. VEGF is expected to play important roles
in inflammation and during normal and pathological
angiogenesis, a process that is associated with wound
healing,  embryonic  development,  and  growth  and
metastasis of solid tumors.16 Elevated levels of VEGF
have been reported in synovial fluids of rheumatoid
arthritis  patients  and  in  sera  from  cancer
patients.17–19
Recently, COX-2 has been shown to enhance basic
fibroblast  growth  factor-induced  angiogenesis
through induction of VEGF in rat sponge implants.20
We  have  therefore  investigated  whether VEGF  can
activate  COX-2  expressed  in  endothelial  cells. The
signalling  mechanism by which the COX isoform is
expressed  in  endothelial  cells  activated with VEGF
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inhibitor,  genistein,  and  protein  kinase C  inhibitor,
staurosporine.
Materials and methods
Cell culture
Human  umbilical  vein  endothelial  cells  (HUVEC)
were obtained from babies born to normal pregnant
women as  previously  described.21 All  patients gave
written informed consent. HUVEC were cultured in
96-well  plates  with  human  endothelial-SFM  basal
growth medium  (Gib Thai, Bangkok, Thailand) con-
taining 10% foetal calf serum (Gib Thai), 100U/ml of
penicillin G sodium and 100mg/ml of streptomycin.
Cells were incubated at 37°C in a humidified incuba-
tor and grown to confluence before use.
Measurement of the COX activity
Confluent  HUVEC  were  gently  washed  twice  with
phosphate-buffered saline (PBS) and incubated with
human  endothelial-SFM  basal  growth  medium
(200ml/well) with no addition, VEGF (0.01, 0.1, 1 or
10ng/ml) alone, genistein (a protein tyrosine kinase
inhibitor;  5mg/ml)  alone,  staurosporine  (a  protein
kinase C inhibitor; 10ng/ml) alone, or  VEGF (10ng/ml)
+ genistein (0.05, 0.5 or 5mg/ml) or staurosporin (0.1,
1 or 10ng/ml) for 24h. After this, the medium was
removed and washed twice with PBS. COX activity was
measured by the production of 6-keto-prostaglandin
(PG) F1a (a stable metabolite of PGI2 that is the major
COX metabolite in endothelial cells) in the replaced
fresh medium containing exogenous arachidonic acid
(10mM for 10min) using an enzyme immunoassay (EIA
kit, Amersham, Buckingham, UK).
Immunoblot (Western blot) analysis
HUVEC  that were untreated (control), treated with
genistein  (5mg/ml)  alone,  staurosporine  (10ng/ml)
alone, VEGF (0.01–50ng/ml) alone, VEGF (10ng/ml)
+  genistein  (5mg/ml)  or VEGF  (10ng/ml)  +  staur-
osporine (10ng/ml) were cultured in six-well plates
(37°C, for 24h). After incubation, cells were extracted
and a specific monoclonal COX-1 or COX-2 antibody
was used to detect the expression of COX isoform as
previously described.22
Measurement of cell viability
Cell  respiration,  an  indicator  of  cell  viability,  was
assessed by the mitochondrial dependent reduction
of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide  (MTT)  to  formazan.23 At  the  end  of  each
experiment,  cells  in  96-well  plates  were  incubated
(37°C, 1h) with MTT (0.2mg/ml) dissolved in culture
medium, after which time the medium was removed
by  aspiration  and  cells  were  solubilized  in  DMSO
(200ml in each well). The extent of reduction of MTT
to  formazan  within  cells  was  quantitated  by  the
measurement  of  optical  density  at  650nm  using  a
microplate reader (BIORAD, California, USA).
Statistical analysis
Results are shown as mean ± standard error of the
mean from triplicate determinations (wells) from at
least  three  separate  experimental  days  (n =  9).
Student’s  paired  or  unpaired  t-tests  were  used  as
appropriate to determine the significance  of differ-
ences  between  means,  and  p <  0.05  was  taken as
statistically significant.
Materials
Staurosporine, genistein, dimethyl sulfoxide (DMSO),
PBS  (pH  7.4),  Trisma  base,  ethylenediamine  tetra-
acetic acid, triton X-100, phenylmethylsulphonyl fluo-
ride,  pepstatin A,  leupeptin,  glycerol,  bromphenol
blue,  2-mercaptoethanol, sodium  dodecyl  sulphate,
anti-rabbit  IgG  antibody,  goat  IgG,  premixed  BCIP/
NBT solution, MTT, penicillin G sodium and strepto-
mycin  were supplied  by  Sigma  Chemical  Company
(St.  Louis,  MO,  USA).  6-keto-PGF1a assay  kits  were
purchased from Amersham (USA). Human endothelial-
SFM basal growth medium and foetal calf serum were
obtained from GibThai. A specific monoclonal COX-1
(human)  or COX-2  (human) antibody was obtained
from  Cayman  Chemical  Company  (Sapphire,  Aus-
tralia).  Recombinant  human  VEGF  was  purchased
from R&D (Minneapolis, MN, USA). Pure nitrocellu-
lose  membrane  (0.45mm)  and  filter  paper  were
purchased from BIO-RAD.
Results
The effects of VEGF on the COX isoform
expressed in HUVEC
Control untreated cells contained COX-1 protein but
not COX-2 protein (Figs. 1 and 2, lane 1). The amount
of COX-1 protein expressed in HUVEC treated with
VEGF (0.01, 0.1, 1, 10 or 50ng/ml) did not change
when compared with control untreated cells at 24h
(Fig. 2). Interestingly, COX-2 protein was induced in
HUVEC treated with VEGF (0.01, 0.1, 1, 10 or 50ng/
ml) in a dose-dependent manner (Fig. 1).
The effects of VEGF on COX activity in HUVEC
In HUVEC treated with VEGF (0.01, 0.1, 1 or 10ng/
ml), COX activity as measured by the production of
6-keto-PGF1a in  the  presence  of  exogenous  arachi-
donic acids (10mM for 10min) was also increased in
a dose-dependent manner. The increased COX activity
in VEGF-treated HUVEC was significant at 0.1ng/ml of
VEGF (p < 0.05, n = 12; Fig. 3).
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viability when compared with the control untreated
cells over a 24h incubation period (p >  0.05,  n =
12).
The effects of genistein (tyrosine kinase
inhibitor) and staurosporine (protein kinase C
inhibitor) on COX activity in VEGF-treated
HUVEC
Interestingly, the increased COX activity as measured
by the production of 6-keto-PGF1a in the presence of
exogenous arachidonic acids (10mM for  10min)  in
HUVEC activated with VEGF (10ng/ml) was inhibited
by genistein (0.05, 0.5, or 5mg/ml, at 24h) in a dose-
dependent manner (Fig. 4A) but not by staurosporine
(0.1, 1, or 10ng/ml, at 24h; Fig. 4B). The inhibition of
increased COX activity in VEGF-treated HUVEC was
significant at 0.5mg/ml of genistein (p < 0.05, n = 12;
Fig. 4A). Moreover, the production of 6-keto-PGF1a in
untreated HUVEC was not affected when cells were
co-incubated with genistein alone (5mg/ml; Fig. 4A)
or staurosporine alone (10ng/ml; Fig. 4B) for 24h.
Genistein  (0.05–5mg/ml)  and  staurosporine
(0.1–10ng/ml)  did  not  affect  cell  viability  when
compared with the control untreated cells over a 24h
incubation period (all > 90% of untreated cells).
The effects of genistein (tyrosine kinase
inhibitor) and staurosporine (protein kinase C
inhibitor) on the COX isoform expressed in
VEGF-treated HUVEC
The induction of COX-2 protein by VEGF (10ng/ml)
in  HUVEC  was  inhibited  by  genistein  (5mg/ml,  at
24h)  but  not  by  staurosporine  (10ng/ml,  at  24h)
(Fig. 5). The amount of COX-1 protein expressed in
HUVEC treated with genistein (5mg/ml) alone, staur-
osporine  (10ng/ml)  alone,  VEGF  +  genistein
(5mg/ml) or VEGF + staurosporine (10ng/ml) at 24h
was  not  changed  when  compared  with  untreated
control cells (Fig. 6).
Discussion
In  the  present  paper,  we  have  shown  that VEGF
could  induce  COX-2  protein  expressed  in  HUVEC
Protein tyrosine kinase mediated COX-2 expressed in VEGF treated HUVEC
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FIG. 1. The effects of VEGF on COX-2 expressed in HUVEC.
COX-2  was detected by Western  blots  using specific  anti-
bodies to COX-2 in cell extracts of HUVEC treated with no
addition (lane 1) or with VEGF (0.01, 0.1, 1, 10 or 50ng/ml;
lanes 2–6) for  24h. Equal amounts of  protein (20mg/lane)
were  loaded in each  lanes. Similar results  were  obtained
with cell extracts from three separate batches of cells. The
significant differences between each band were compared
by scanner densitometry using an image one-dimensional
program (densitometry unit).
FIG. 2. The effects of VEGF on COX-1 expressed in HUVEC.
COX-1  was detected by Western  blots  using specific  anti-
bodies to COX-2 in cell extracts of HUVEC treated with no
addition (lane 1) or with VEGF (0.01, 0.1, 1, 10 or 50ng/ml;
lanes 2–6) for  24h. Equal amounts of  protein (20mg/lane)
were loaded in each lane. Similar results were obtained with
cell  extracts  from  three  separate  batches  of  cells.  The
significant differences between each band were compared
by scanner densitometry using an image one-dimensional
program (densitometry unit).
FIG. 3. Dose-dependent effects of VEGF (0.01–10ng/ml) on
COX activity in HUVEC. COX activity was measured by the
formation  of  6-keto-PGF1a in  the  presence  of  exogenous
arachidonic  acid  (10mM,  10min).  Data  are  expressed  as
mean  ±  standard error  of  the mean  of  12 determinations
from at least four separate experimental days. * p <  0.05
when compared with untreated HUVEC at 24h (C).while the amount of COX-1 protein expression was
not  affected. VEGF  also  increased  COX  activity  as
measured  by  the  production  of  6-keto-PGF1a (a
stable  metabolite  of  PGI2)  in  a  dose-dependent
manner. This increased COX activity was dependent
on COX-2; Fig. 3 clearly shows that VEGF increased
6-keto-PGF1a production in  the  presence  of  exoge-
nous arachidonic acid in a dose-dependent manner,
while COX-2 protein only (not COX-1 protein) was
induced  (Figs.  1  and  2).  Moreover,  the  increased
COX  activity  and  COX-2  protein  in  VEGF-treated
HUVEC  were  decreased  when  cells  were  co-incu-
bated with genistein (tyrosine kinase inhibitor; Figs.
4 and 5) while COX-1 protein was unaffected (Fig.
6). However, the increased COX activity and COX-2
protein  in VEGF-treated  HUVEC  were  not  changed
when  cells  were  co-incubated  with  staurosporine
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FIG. 4. The effects of (A) genistein (GEN) (0.05–5mg/ml) and
(B)  staurosporine  (SRS)  (0.1–10ng/ml)  on  COX  activity  in
HUVEC treated with VEGF (10ng/ml) for 24h. COX activity
was  measured  by  the  formation  of  6-keto-PGF1a in  the
presence  of  exogenous  arachidonic  acid  (10mM,  10min).
Data are expressed as mean ± standard error of the mean of
12 determinations from at least four separate experimental
days. * p < 0.05 when compared with VEGF-treated HUVEC at
24h; 
+ p < 0.05 when compared with untreated HUVEC at 24h
(C).
FIG.  5.  The  effects  of  genistein  (GEN)  and  staurosporine
(SRS) on COX-2 expressed in VEGF-treated HUVEC. COX-2
was detected by Western blots using specific antibodies to
COX-2  in cell  extracts  of  HUVEC  treated with no addition
(lane 1), with genistein (5mg/ml) alone (lane 2), with staur-
osporine  (10ng/ml)  alone  (lane  3),  with  VEGF  (10ng/ml)
alone (lane 4), with VEGF (10ng/ml) + genistein (5mg/ml; lane
5) or with VEGF (10ng/ml) + staurosporine (10ng/ml; lane 6)
for 24h. Equal amounts of protein (20mg/lane) were loaded
in each lane. Similar results were obtained with cell extracts
from three separate batches of cells. The significant differ-
ences  between  each  band  were  compared  by  scanner
densitometry  using  an  image  one-dimensional  program
(densitometry unit).
FIG.  6.  The  effects  of  genistein  (GEN)  and  staurosporine
(SRS) on COX-1 expressed in VEGF-treated HUVEC. COX-1
was detected by Western blots using specific antibodies to
COX-1  in cell  extracts  of  HUVEC  treated with no addition
(lane 1), with genistein (5mg/ml) alone (lane 2), with staur-
osporine  (10ng/ml)  alone  (lane  3),  with  VEGF  (10ng/ml)
alone (lane 4), with VEGF (10ng/ml) + genistein (5mg/ml; lane
5) or with VEGF (10ng/ml) + staurosporine (10ng/ml; lane 6)
for 24h. Equal amounts of protein (20mg/lane) were loaded
in each lane. Similar results were obtained with cell extracts
from three separate batches of cells. The significant differ-
ences  between  each  band  were  compared  by  scanner
densitometry  using  an  image  one-dimensional  program
(densitometry unit).(protein kinase C inhibitor; Figs. 4 and 5). The COX-
1  protein  was  also  unaffected  when  cells  were
co-incubated  with  staurosporin  (Fig.  6). Therefore,
our  results  showed  that  the  induction  of  COX-2
in  HUVEC  treated  with  VEGF  was  mediated
through protein tyrosine kinase but  not by  protein
kinase C.
VEGF  is  an  endothelium-specific  peptide  that
potently  stimulates  angiogenesis,  vasodilation  and
microvascular  hyperpermeability.  Previous  study
showed that VEGF rapidly increased phosphorylation
and activity of cytosolic PLA2, and stimulated release
of  arachidonic  acid  in  HUVEC  resulted  in  prosta-
glandin  production.24 However,  it  was  not  shown
whether  the  COX  isoform  mediates  these  effects.
Therefore, the uses of exogenous arachidonic acid as
substrates will help to evaluate COX enzyme directly.
Recently, it has been shown that VEGF upregulates
COX-1  in  bovine  aortic  endothelial  cells  and
HUVEC.25 In contrast, here, our results showed that
VEGF  directly  increased  COX  activity  in  HUVEC
through  the  induction  of  COX-2.  However,  the
amount of COX-1 protein expressed in HUVEC treated
with  VEGF  did  not  change  when  compared  with
untreated HUVEC. A major concern of the different
results  was  the  cross-reactivity  and  source  of  the
antibodies used. For COX-1 detection, Bryant et al.25
used a 1 : 7500 dilution of anti-sheep COX-1 raised to
rabbit while we used a 1 : 2000 dilution of specific
COX-1  monoclonal  antibody  (clone  CX-111).  For
COX-2  detection, Bryant et al.25 used a 1  :  10,000
dilution of anti-human COX-2 raised to rabbit while
we  used  a  1  :  2000  dilution  of  specific  COX-2
monoclonal  antibody.  The  other  explanation  was
whether  another  COX  isoform  (COX-3)  may  exist.
However,  these  points  could  be  argued  and  await
elucidation.
Moreover, we also showed that the increased COX
activity  and  COX-2  protein  in  HUVEC  treated with
VEGF was mediated through protein tyrosine kinase,
but  not  protein  kinase  C  (Figs.  4  and  5).  These
findings were correlated with previous studies show-
ing  that VEGF  receptors  on  endothelial  cells  were
acted via protein tyrosine kinase26–28 and the induc-
tion of COX-2 in endothelial cells by several mitogens
was  mediated  through  protein  tyrosine  kinase.29
Therefore, the downstream regulation of PG produc-
tion in HUVEC activated with VEGF was affected at
several  sites  such  as  COX-2  protein, tyrosine  phos-
phorylation and phospholipase A2.
In summary, our studies are the first to show that
COX-2 can be induced in HUVEC treated with VEGF
through protein tyrosine kinase. VEGF is known to be
involved in pathological conditions such as inflamma-
tion, atherosclerosis and carcinogenesis.16 Thus, the
uses of specific COX-2 inhibitors in these conditions,
in  which  VEGF  was  involved,  might  have  a
role.30–32
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